Related Experiment Video
Updated: Aug 4, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
New-Onset Alzheimer's Disease and Normal Subjects 100% Differentiated by P300
B W Jervis1, C Bigan2, M W Jervis1
11 Personal Contribution, Sheffield, United Kingdom.
American Journal of Alzheimer'S Disease and Other Dementias
|February 9, 2019
Summary
This study accurately detected new-onset Alzheimer's disease using electroencephalogram analysis. Back-projected independent components of the P300 peak show promise for early Alzheimer's detection.
Area of Science:
- Neuroscience
- Biomedical Engineering
Background:
- Early detection of Alzheimer's disease (AD) is crucial for timely intervention and management.
- Evoked potential analysis has shown potential for identifying neurological conditions.
Purpose of the Study:
- To investigate the efficacy of evoked potential analysis, specifically P300 peak components, in differentiating new-onset Alzheimer's disease from healthy controls.
- To achieve 100% accuracy in detecting early-stage Alzheimer's disease.
Main Methods:
- Utilized an oddball, auditory-evoked potential paradigm.
- Analyzed back-projected independent components (BICs) of the P300 peak from electroencephalogram (EEG) data.
- Applied artifact removal, clustering, selection, normalization, and classification using neural networks, Bayes classifiers, and voting strategies.
Main Results:
- Achieved 100% accuracy in distinguishing subjects with new-onset Alzheimer's disease from healthy controls.
- Demonstrated the effectiveness of BICs derived from P300 peaks for accurate classification.
Conclusions:
- Back-projected independent components of the P300 peak offer a highly accurate method for detecting new-onset Alzheimer's disease.
- This technique holds potential for presymptomatic detection and application to other neurological conditions and evoked potentials, warranting further multicenter validation.
Keywords:
Alzheimer’s diseaseBayes classifierP300PSFAMartificial neural networkauditory-evoked potentialbiomarkersindependent components analysisMore Related Videos
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
09:38Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...